Long-term safety and tolerability of donepezil 23mg in patients with moderate to severe Alzheimers disease

20Citations
Citations of this article
68Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background: Donepezil (23mg/day) is approved by the US Food and Drug Administration for the treatment of patients with moderate to severe Alzheimers disease (AD). Approval was based on results from a 24-week, randomized, double-blind study of patients who were stable on donepezil 10mg/day and randomized 2:1 to either increase their donepezil dose to 23mg/day or continue taking 10mg/day. The objective of this study was to assess the long-term safety and tolerability of donepezil 23mg/day in patients with moderate to severe AD. Methods. Patients who completed the double-blind study and were eligible could enroll into a 12-month extension study of open-label donepezil 23mg/day. Clinic visits took place at open-label baseline and at months 3, 6, 9, and 12. Safety analyses comprised examination of the incidence, severity, and timing of treatment-emergent adverse events (AEs); changes in weight, electrocardiogram, vital signs, and laboratory parameters; and discontinuation due to AEs. Results: 915 double-blind study completers were enrolled in the open-label extension study and 902 comprised the safety population. Mean treatment duration in this study was 10.33.5months. In total, 674 patients (74.7%) reported at least one AE; in 320 of these patients (47.5%) at least one AE was considered to be possibly or probably study drug related. The majority of patients reporting AEs (81.9%) had AEs of mild or moderate severity. There were 268 patients (29.7%) who discontinued early, of which 123 (13.6%) were due to AEs.Patients increasing donepezil dose from 10mg/day in the double-blind study to 23mg/day in the extension study had slightly higher rates of AEs and SAEs than patients who were already receiving 23mg (78.0% and 16.9% vs 72.8% and 14.0%, respectively). The incidence of new AEs declined rapidly after the first 2weeks and remained low throughout the duration of the study. Conclusion: This study shows that long-term treatment with donepezil 23mg/day is associated with no new safety signals. The elevated incidence of AEs in patients increasing the dose of donepezil from 10mg/day to 23mg/day was limited to the initial weeks of the study. © 2012 Tariot et al.; licensee BioMed Central Ltd.

Cite

CITATION STYLE

APA

Tariot, P., Salloway, S., Yardley, J., MacKell, J., & Moline, M. (2012). Long-term safety and tolerability of donepezil 23mg in patients with moderate to severe Alzheimers disease. BMC Research Notes, 5. https://doi.org/10.1186/1756-0500-5-283

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free